Microvessel density (MVD), assessed via von Willebrand factor expression, and microvessel count, evaluated through CD34 or CD31 immunostaining, are significantly elevated in lesional skin from patients with plaque- or tumor-stage MF, as well as in advanced MF (stage III and IV). This evidence concerns the gene CD34 and mycosis fungoides.